Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)
Phase
3Span
215 weeksSponsor
ViiV HealthcareFrancistown
Recruiting
Healthy Volunteers
The Tatelo Plus Study
Phase
1/2Span
180 weeksSponsor
National Institute of Allergy and Infectious Diseases (NIAID)Francistown
Recruiting
1-2 of 2